News Center

Home page

Peak Report

News reports

Cefmenoxime Hydrochloride for Injection Instructions

Release time:

2020-07-31

Approval Date: March 29, 2007
First Amendment Date: September 16, 2009
Second Amendment Date: December 01, 2013
Third Amendment Date: October 31, 2014
Fourth Amendment Date: December 01, 2015
Fifth Amendment Date: december 03, 2015

Cefmenoxime Hydrochloride for Injection Instructions
Please read the instructions carefully and use

[Drug Name]
General Name: Cefmenoxime Hydrochloride for Injection
English Name: Cofmenoxime Hydrochloride for Injection
Chinese Pinyin: Zhusheyong Yansuan Toubaojiawo
[Ingredients] The main ingredient of this product is Cefmenoxime Hydrochloride, whose chemical name is:(6R,7R) -7-[(Z)-2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-[[(1-methyl-1H-tetrazol-5-yl)-thio] methyl]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-Formic acid hydrochloride (2:1).
chemical structural formula:

molecular formula:(C16H17N9O5S3)2 · HCl molecular weight: 1059.58 auxiliary material: anhydrous sodium carbonate
[properties] this product is white to light yellow crystal or crystalline powder.
[Indications] This product is applicable to cefmenoxime-sensitive Streptococcus (except Enterococcus), Streptococcus pneumoniae, Digestococcus, Digestococcus, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Haemophilus influenzae, Bacteroides, etc. caused by the following infections:
1, pneumonia, bronchitis, bronchiectasis complicated with infection, secondary infection of chronic respiratory diseases; Lung abscess, empyema;
2, pyelonephritis, cystitis; Bartholin's adenitis, endometritis, uterine adnexitis, pelvic inflammation, parauterine tissue inflammation;
3, cholangitis, cholecystitis, liver abscess; Peritonitis;
4, secondary infection of burns and surgical trauma;
5;
6. Cerebrospinal meningitis.
[Specifications] 0.25g, 0.5g, 1.0g, 2.0g (by C16H17N9O5S3)
[Usage and Dosage] Usage: This product is dissolved in 0.9 sodium chloride injection or glucose injection for intravenous drip.
In addition, for adults, 0.5g-2g of this product can also be added to the rehydration of sugar solution, electrolyte solution or amino acid preparation for intravenous drip within 30 minutes to 2 hours. For children, one dose can also be considered to be added to the fluid infusion, and intravenous drip is carried out within 30 minutes to 1 hour. For static injection, inject about 5ml of dissolved solution into the bottle for dissolution when using 1g, and inject not less than 100ml of dissolved solution into the bottle for drip.
Dosage: 1. Adults: mild infection: 1-2g a day, divided into 2 intravenous drips; Moderate and severe infection: it can be increased to 4g a day, divided into 2-4 intravenous drips. The dose can also be adjusted according to the clinical situation. 2. Children: mild infection: 40-80mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Moderate and severe infection: it can be increased to 160mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip; Cerebrospinal meningitis: it can be increased to 200mg per kilogram of body weight per day, divided into 3-4 times of intravenous drip.
[Adverse Reactions] 1. Serious Adverse Reactions:
⑴ Sometimes Shock (less than 0.1%) is caused. Therefore, careful observation should be made. In case of abnormal symptoms such as discomfort, abnormal feeling in mouth, wheezing, vertigo, defecation, tinnitus, sweating, etc., administration should be stopped and appropriate treatment should be carried out.
(2) Occasionally, severe renal dysfunction such as acute renal insufficiency (less than 0.1%), so renal function should be checked regularly and carefully observed. If abnormal, drug administration should be stopped and appropriate treatment should be carried out.
(3) Sometimes granulocytopenia (less than 0.1-5%) or no granulocytosis (less than 0.1). In addition, other cephalosporin antibiotics have been reported to cause hemolytic anemia. In case of abnormality, administration should be stopped and appropriate management should be carried out. Severe colitis with bloody stool, such as pseudomembranous colitis, sometimes occurs (less than 0.1 percent), such as abdominal pain and repeated diarrhea, should be stopped immediately and managed appropriately.
(5) Interstitial pneumonia and PIE syndrome (less than 0.1 percent) with fever, cough, dyspnea, chest X-ray abnormalities, eosinophilia, etc., should be discontinued and managed appropriately.
(6) In patients with renal insufficiency, spasticity and the like are sometimes caused when a large amount of drugs are administered.
2, Other Adverse Reactions
⑴ Allergy: Rash, Urticaria, Erythema, Pruritus, Fever, Lymphadenopathy, Arthralgia;
⑵ Blood: Anemia, Eosinophilia, Thrombocytopenia;
(3) Liver: ALT, AST, ALP, LDH Elevation, Jaundice, γ-GTP Elevation;
(4) Digestive Tract);
(5) Flora disorder: stomatitis, candidiasis;
(6) Vitamin deficiency: vitamin K deficiency symptoms (hypocoagulinemia, bleeding tendency, etc.), vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.);
(7) Others: burnout, staggering, headache.
[Taboo] The product and cephalosporins have a history of allergic reactions are prohibited.
[Precautions] 1. The following patients take drugs carefully
(1) Patients with a history of allergy to penicillin antibiotics;
(2) I or my parents and brothers have patients who are prone to allergic symptoms such as bronchial asthma, rash, urticaria, etc.
(3) Patients with severe renal dysfunction (continuous increase of blood drug concentration may occur);
(4) Elderly Patients (Decline in Physiological Function, side effects are easy to occur; Sometimes vitamin K deficiency and bleeding tendency);
(5) people with poor oral feeding or intravenous nutrition, and people with poor general state (sometimes vitamin K deficiency can be caused, so careful observation should be made);
2, because shock reaction may occur, so detailed consultation is required. It is recommended to do skin allergy test before injection. First aid should be done in advance in the event of shock.
3, the use of this product, the best regular liver function, kidney function, blood and other tests.
4. Interference to diagnostic reagents: In addition to the reaction of urine sugar test strip (TES-tape), false positive reaction may occur when urine sugar test is carried out with Banns reagent, Flynn reagent and Clinitest (sheet reagent containing copper sulfate), and direct antiglobulin (Coombs) test is positive, please pay attention.
[Medication for pregnant and lactating women] The safety of medication for pregnancy has not been established, and the use of this product by pregnant and lactating women should be weighed.
[Use in children] The safety of use in preterm infants and newborns is uncertain.
[Elderly medication] Most elderly patients have decreased physiological functions and are prone to side effects. Sometimes vitamin K deficiency and bleeding tendency.
[Drug Interactions]
1. Furananilic Acid Diuretics: It has been reported that renal dysfunction can be aggravated when combined with other cephalosporins. Therefore, renal function should be paid attention to when combined.
2. Ethanol (drinking): alcohol intake due to drinking, sometimes flushing, nausea, tachycardia, hyperhidrosis, headache, etc., so alcohol intake should be avoided during and at least one week after medication.
[Drug Overdose] Unclear
[Pharmacology and Toxicology] Pharmacological Effects
Cefmenoxime is a semi-synthetic cephalosporin broad-spectrum antibiotic that achieves bactericidal effects by inhibiting the biosynthesis of bacterial cell walls. This product has a strong antibacterial effect on gram-negative bacteria due to its good extracellular membrane permeability, stability to β-lactamase, and strong affinity to penicillin binding proteins (PBPs)1A, 1B and 3, which has a strong barrier to the formation of cell wall mucin cross-linking.
In vitro tests show that this product has an effect on both gram-positive and gram-negative bacteria. The antibacterial activity of Gram-positive bacteria was stronger than that of cefotiam (CTM) and cefazolin (CEZ) in terms of Streptococcus pyogenes and Streptococcus pneumoniae. It has strong antibacterial power against digestive cocci and digestive streptococcus. The antibacterial power to Gram-negative bacteria was slightly stronger than CTM and much stronger than CEZ in terms of E. coli and pneumoniae. The antibacterial force against influenza bacilli, Proteus, Serratia marcescens, Citrobacter, and intestinal bacteria was stronger than CTM, and much stronger than CEZ. In addition, it also shows strong antibacterial power to Bacteroides.
Toxicology study Reproductive toxicity: Animal experiments showed that in rats, rabbits and monkeys during the organ formation period of administration, each administration group of rabbits had female rabbit death or abortion, but all kinds of animals had no teratogenic effect. There was no obvious abnormality in general reproductive toxicity test and perinatal reproductive toxicity test in rats. [Pharmacokinetics] According to literature data, the peak blood drug concentration can reach 50.9mg/L and 135.7mg/L respectively after a single intravenous infusion of 0.5g and 1g of this drug in adults with normal renal function, and 75mg/L and 125mg/L respectively after a single intravenous infusion of 0.5g and 1g of cefmenoxime. The serum elimination half-life of this product is about 1 hour. It is well distributed in various tissues and body fluids after administration. It can also cross the blood-brain barrier. The drug is mainly excreted through the kidney. After an intravenous injection or intravenous drip of 0.5g, 1g and 2g of the drug in adults (with normal renal function), the excretion rate in urine within 6 hours is 60-82%. In addition, the urine drug concentration after 1g of intravenous drip was about 4400 μg/L for 0-2 hours, about 750 μg/L for 2-4 hours, and about 120 μg/L for 4-6 hours. Children (with normal renal function) had the same urinary excretion rate at 6 hours after a single intravenous injection or intravenous drip of 10, 20, and 40 mg/kg as adults.
[Storage] Shaded, airtight, and stored in a cool and dry place (not more than 20 ℃).
[Package] Antibiotic Glass Bottle, 0.25g × 2 Bottle/Box, 0.25g × 1 Bottle/Box; 0.5g × 1 bottle/box, 0.5g × 2 bottle/box; 1.0g × 1 bottle/box; 2.0g × 2 bottles/box, 2.0g × 1 bottle/box; 0.25g × 5 bottles/box, 0.5g × 5 bottles/box, 1.0g × 5 bottles/box.
[Validity Period] 24 Months
[Implementation Standard] "Chinese Pharmacopoeia" 2015 Edition II
[Approval Document No.] Chinese Medicine Standard H20041145( 0.25g), Chinese Medicine Standard H20041146( 0.5g), Chinese Medicine Standard H20041147(1.0g), Chinese Medicine Standard H20093940( 2.0g)
[Production Enterprise] Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd. Address: no. 58, Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax: 0579-82661998 Postal Code: 321075
Website:
www.zjjfyy.com.cn

More information

City Red Cross thanks spike help "anti-epidemic"

On February 26, Jinhua City Red Cross Party Secretary, Executive Vice President Shi Yiwei and his entourage to visit the peak, the peak in the prevention and control of the new coronary pneumonia epidemic actively contribute to love, brave social responsibility of the great love and kindness to express gratitude. Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, and Xiang Chongping, deputy general manager of the group company, had a discussion with Vice President Shi Yiwei and his party. In order to solve the difficult problems for caring enterprises to resume work and production, the Municipal Red Cross Society, based on its own functional positioning and giving full play to its unique advantages, conducted a large feedback and return visit to caring enterprises, and jointly established three Red Cross volunteer service teams, including traditional Chinese medicine service, psychological assistance, and emergency rescue training, to take "eight measures" to help caring enterprises resume work and production. Vice President Shi Yiwei led the backbone of three volunteer service teams to the peak for a return visit, expressing his gratitude for the contribution made by the peak in the prevention and control of the new coronary pneumonia epidemic, and sent a letter of thanks and the "New Coronary Pneumonia Prevention and Control Enterprises Resuming Work and Resuming Production Protection Manual". Chairman Jiang Xiaomeng introduced the industrial layout, production and operation of the peak, focusing on the resumption of work and production of the peak enterprises, and put forward opinions and suggestions on the reduction and exemption of basic electricity charges for enterprises, the support policies for small and medium-sized enterprises, and the payment of "five insurance and one fund. (Reporter Ni Yingzhen)

2020

07-15

Peak 2013 corporate bonds complete principal and interest payments

News from our newspaper On November 20, Zhejiang Jianfeng Group Co., Ltd. successfully completed the payment of principal and interest on 2013 corporate bonds (Phase II) (hereinafter referred to as "13 Jianfeng 02"). At this point, all the corporate bonds approved for issuance in 2013 have been paid. In 2013, with the approval of document No. [2013]595 of China Securities Regulatory Commission, the company was allowed to issue corporate bonds with a face value of no more than 0.6 billion yuan to the public, with a debt rating of AA +. On June 5, 2013, the Company issued the 2013 Corporate Bonds (Phase I) ("13 Peak 01"), which raised $0.3 billion at a coupon rate of 4.90 per cent, 1.55 percentage points lower than the then five-year benchmark interest rate for bank loans. On November 20, 2014, "13 Peak 02" was successfully issued, raising 0.3 billion yuan again at a coupon rate of 5.09, and was listed on the Shanghai Stock Exchange on December 11, 2014. The ability to raise 0.6 billion yuan from the capital market at a lower cost reflects investors' recognition of the company's "cement + pharmaceutical" dual business structure and expectations of the company's good operating performance. On June 5, 2018, the first issue of Jianfeng Group's 2013 corporate bonds was due to complete the payment of principal and interest, and now the second issue of corporate bonds has also successfully completed the payment of principal and interest. In the real economic growth is weak, business operations continue to explode, the company in a short period of time successfully completed two issues of a total of 0.6 billion yuan of corporate bonds principal and interest payment work, fully reflecting the company's good operating results in recent years.

2020

07-31

Company Leaders Attend Jinhua Development Conference

News from our newspaper On November 17, the second 2019 Jinhua Development Conference with the theme of "Insist on high-quality integration into the Yangtze River Delta to build a metropolitan area" opened in Jinhua, Zhejiang. More than a thousand people from the scientific and educational circles, business circles, and overseas Chinese from home and abroad Business people, representatives of "New Golden Chinese" and representatives of outstanding Jinhua students attended the meeting. Group leaders Jiang Xiaomeng, Yu Jianhong and Huang Jinlong attended the relevant activities of the conference. As a representative of the Jinhua business community, Jiang Xiaomeng, chairman of the group company, made a keynote speech at the "Scientist" and "Entrepreneur" Innovation Dialogue of the Development Conference, expressing his views on how Jinhua enterprises can improve their technological competitiveness. As the head of Jinhua local enterprise with a history of more than 60 years, Jiang Xiaomeng has a profound experience in promoting the development of enterprises through science and technology. Combined with the reality of peak scientific and technological innovation, he pointed out in his speech that the improvement of scientific and technological innovation ability is an urgent event for Jinhua small and medium-sized enterprises. Private enterprises cannot achieve high-quality development without the support of scientific and technological forces; with the progress of society, the improvement of people's living standards and the continuous improvement of cultural quality, the demand for products and the pursuit of product quality have also undergone qualitative changes. Only products with scientific and technological connotations can attract consumers. He suggested that the government and relevant institutions should establish an information platform to further understand the scientific and technological support that enterprises need in the transformation, understand what kind of help scientific and technological personnel can provide to enterprises, do a good job in the information docking of scientists and entrepreneurs, further attract investment and wisdom, give full play to the scientific and technological achievements of academicians and experts and the capital advantages of businessmen at home and abroad, and promote Jinhua enterprises to better integrate into Changsan

2020

07-31

Company Leaders Attend Jinhua Development Conference

2020

07-22

The Party Committee of the Group conducts thematic education and concentrated study.

On November 12, the Party Committee of the Group Company held a "Do not forget your initiative mind, Keeping in mind the mission" thematic education and study meeting to focus on the relevant spirit of the central and higher Party committees on thematic education and the key points in the "Decision of the Central Committee of the Communist Party of China on Adhering to and Improving the Socialist System with Chinese Characteristics, Promoting the Modernization of the National Governance System and Governance Capacity" previously held at the Fourth Plenary Session of the 19th CPC Central Committee of the 19th CPC Central Committee, and make arrangements for further promoting thematic education in the whole group. According to the central government's schedule for the second batch of thematic education, the group party committee requires all party members and cadres to deeply understand the significance of carrying out the thematic education of "not forgetting the original heart and keeping in mind the mission", and firmly grasp the "keep the original heart, undertake the mission, find the gap, and grasp the implementation" The general requirements of the group party committee members will also go to various enterprises separately in the near future, carry out research on the development of theme education, the current difficulties faced by enterprises and the issues of concern to employees, so as to achieve the effect of closely combining theme education with the promotion of enterprise management, and strengthening the close combination of party building and enterprise development. (this newspaper reporter)

2020

07-31

Company Leaders Attend Jinhua Development Conference

2020

07-31

< 1...26 27 28...61 > 跳转到页